Galectin Therapeutics is part of the healthcare sector and is in the drug manufacturers industry. The company CEO is Harold H. Shlevin. Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.



Previous Intraday Performance:

The GALT shares had a previous change of 3.73% which opened at 4.67 and closed at 4.73. It moved to an intraday high of 4.76 and a low of 4.51.

SeekingAlpha:  Conatus flop fails to move NASH players

Historical Performance:

Over the last five trading days, GALT shares returned -5.40% and in the past 30 trading days it returned 14.25%. Over three months, it changed 25.46%. In one year it has changed 7.01% and within that year its 52-week high was 9.49 and its 52-week low was 3.10. GALT stock is 52.58% above its 52 Week Low.

Our calculations result in a 200 day moving average of 5.22 and a 50 day moving average of 4.87. Right now, GALT stock is trading -9.40% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Conatus flop fails to move NASH players

Liquidity:

The company has a market cap of $215.5m with 45.6m shares outstanding and a float of 37.9m shares. Trading volume was 328,554 shares and has experienced an average volume of 462,006 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Galectin Therapeutics was -0.38 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.08.

Below was the last reported quarterly earnings per share:
12-31-2018:  -0.08
09-30-2018:  -0.07
06-30-2018:  -0.11
03-31-2018:  -0.12

The next earnings report will be: 03-28-2019

The long-term trend of the EPS is an important number as it indicates the present value of Galectin Therapeutics; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but the year over year change has been -14.29%.



Indicators Also to Watch:

Based on the latest filings, there is 20.40% of insider ownership and 18.20% of institutional ownership.

I calculated the beta to be 3.71

Business Wire:  CynergisTek, Inc. Sells Managed Print Services Business to Vereco, LLC for $30 Million

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 306.67%, return on assets is -228.56% and price-to-book is 12,379.63.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here